Charles River upgraded by Citigroup with a new price target
$CRL
Biotechnology: Commercial Physical & Biological Resarch
Health Care
Citigroup upgraded Charles River from Sell to Neutral and set a new price target of $175.00 from $155.00 previously
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 5/23/2025 | $182.00 | Neutral → Buy | Redburn Atlantic |
| 5/14/2025 | $179.00 | Hold → Buy | TD Cowen |
| 5/8/2025 | $170.00 | In-line → Outperform | Evercore ISI |
| 3/21/2025 | $190.00 → $170.00 | Buy → Neutral | Goldman |
| 3/4/2025 | $155.00 → $175.00 | Sell → Neutral | Citigroup |
| 3/3/2025 | $188.00 | Sell → Neutral | Redburn Atlantic |
| 1/22/2025 | Outperform → Mkt Perform | William Blair | |
| 1/17/2025 | $250.00 → $185.00 | Buy → Neutral | UBS |
Charles River Laboratories International, Inc. (NYSE:CRL) and CHDI Foundation, Inc., today announced an extension of their ongoing drug discovery partnership into the foreseeable future. The organizations began working together in 2005 to expedite therapeutic development for Huntington's disease (HD), a genetic neurological disorder that causes the progressive dysfunction of nerve cells in the brain. The extension in 2025, marking the 20-year anniversary of the collaboration, will allow more flexible activity across Charles River's global network of scientific expertise and provide greater integration into CHDI's programs. "For two decades, we've been proud to be close partners of CHDI,"
Charles River Laboratories International, Inc. (NYSE:CRL) announced today that it will present at the Bank of America 2025 Health Care Conference on Wednesday, May 14th, at 8:40 a.m. PT (11:40 a.m. ET). Management will provide an overview of Charles River's strategic focus, business developments, and recent trends. A live webcast of the presentation will be available through a link that will be posted on the Investor Relations section of the Charles River website at ir.criver.com. A webcast replay will be accessible through the same website after the presentation and will remain available for at least two weeks. About Charles River Charles River provides essential products and services t
– First-Quarter Revenue of $984.2 Million – – First-Quarter GAAP Earnings per Share of $0.50 and Non-GAAP Earnings per Share of $2.34 – – Increases 2025 Guidance – – Repurchased $350 Million of Common Stock in First Quarter of 2025 – Charles River Laboratories International, Inc. (NYSE:CRL) today reported its results for the first quarter of 2025. For the quarter, revenue was $984.2 million, a decrease of 2.7% from $1,011.6 million in the first quarter of 2024. The impact of foreign currency translation reduced reported revenue by 0.9%. Excluding this impact, revenue decreased 1.8% on an organic basis driven by declines in all three business segments. In the first quarter of 2025, the
8-K - CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (0001100682) (Filer)
SD - CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (0001100682) (Filer)
SCHEDULE 13G/A - CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (0001100682) (Subject)
4 - CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (0001100682) (Issuer)
4 - CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (0001100682) (Issuer)
4 - CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (0001100682) (Issuer)
Redburn Atlantic upgraded Charles River from Neutral to Buy and set a new price target of $182.00
TD Cowen upgraded Charles River from Hold to Buy and set a new price target of $179.00
Evercore ISI upgraded Charles River from In-line to Outperform and set a new price target of $170.00
– First-Quarter Revenue of $984.2 Million – – First-Quarter GAAP Earnings per Share of $0.50 and Non-GAAP Earnings per Share of $2.34 – – Increases 2025 Guidance – – Repurchased $350 Million of Common Stock in First Quarter of 2025 – Charles River Laboratories International, Inc. (NYSE:CRL) today reported its results for the first quarter of 2025. For the quarter, revenue was $984.2 million, a decrease of 2.7% from $1,011.6 million in the first quarter of 2024. The impact of foreign currency translation reduced reported revenue by 0.9%. Excluding this impact, revenue decreased 1.8% on an organic basis driven by declines in all three business segments. In the first quarter of 2025, the
Charles River Laboratories International, Inc. (NYSE:CRL) will release first-quarter 2025 financial results on Wednesday, May 7th, before the market opens. A conference call has been scheduled to discuss this information on Wednesday, May 7th, at 9:00 a.m. ET. Investors will have the opportunity to listen to a live webcast of the conference call through the Investor Relations section of the Company's website at ir.criver.com. A replay will be accessible through the same website. About Charles River Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate the
– Fourth-Quarter Revenue of $1.00 Billion and Full-Year Revenue of $4.05 Billion – – Fourth-Quarter GAAP Loss per Share of $(4.22) and Non-GAAP Earnings per Share of $2.66 – – Full-Year GAAP Earnings per Share of $0.20 and Non-GAAP Earnings per Share of $10.32 – – Provides 2025 Guidance – – Company Plans Stock Repurchases of Approximately $350 Million in 2025 – Charles River Laboratories International, Inc. (NYSE:CRL) today reported its results for the fourth quarter and full-year 2024 and provided guidance for 2025. For the quarter, revenue was $1.00 billion, a decrease of 1.1% from $1.01 billion in the fourth quarter of 2023. The impact of foreign currency translation reduced report
3 - CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (0001100682) (Issuer)
3 - CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (0001100682) (Issuer)
3 - CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (0001100682) (Issuer)
SC 13G - CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (0001100682) (Subject)
SC 13G/A - CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (0001100682) (Subject)
SC 13G/A - CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (0001100682) (Subject)
– Board Approves Appointment of Four New Directors – – Strategic Planning and Capital Allocation Committee of the Board to Conduct Comprehensive Strategic Review of the Company's Business – – Enters into Cooperation Agreement with Elliott Investment Management – Charles River Laboratories International, Inc. (NYSE:CRL) today announced that four new directors will join its Board of Directors and that four long-time members of the Board will not seek re-election at the 2025 Annual Meeting of Shareholders. The Company also announced changes to its Board committees and a strategic review of the Company's business focused on enhancing long-term value for shareholders. Charles River's Board o
Agreement establishes Charles River as the preferred partner for Autobahn Labs, leveraging drug discovery and development capabilities to accelerate the translation of academic discoveries into novel therapeutics Under the agreement, Charles River will make an equity investment in Autobahn Labs Justin Bryans, Chief Scientific Officer, Discovery at Charles River, named to Autobahn's Board of Directors Charles River Laboratories International, Inc. (NYSE:CRL) and Autobahn Labs, a Samsara BioCapital-backed virtual accelerator for academic biotech, today announced a collaborative relationship that establishes Charles River as the preferred research partner to support Autobahn's grow
Charles River Laboratories International, Inc. (NYSE:CRL) today announced the appointment of Reshema Kemps-Polanco, Executive Vice President and Chief Commercial Officer, Novartis US, to its Board of Directors. Ms. Kemps-Polanco has extensive pharmaceutical industry experience in leading commercial organizations that will provide a wealth of healthcare business leadership knowledge and sales and marketing expertise to Charles River's Board. As a member of the Board, Ms. Kemps-Polanco will serve on the Compensation and Strategic Planning and Capital Allocation Committees. "Reshema Kemp-Polanco's deep industry experience at two of the top-10, global pharmaceutical companies and demonstrated